MedTrace Logo

Incorporation of AlloMaxTM in Breast Reconstruction Ver8-15-12

NCT01679223 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2015-01-09

No results posted yet for this study

Summary

The purpose of this study is to measure the level of AlloMax™ incorporation (cellular infiltration, collagen production, and neovascularization) in human breast reconstruction. The hypothesis is that the AlloMaxTM will have incorporation equivalent to adjacent breast capsule at the 3-4 month time point.

Conditions

Sponsors & Collaborators

  • University of Nevada, Las Vegas

    lead OTHER

Principal Investigators

  • Kayvan Taghipour-Khiabani, M.D. · University of Nevada School of Medicine

  • William A Zamboni, M.D. · University of Nevada School of Medicine

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2018-11-30
Completion
2018-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01679223 on ClinicalTrials.gov